In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
about
Functional evidence for a 5-HT2B receptor mediating contraction of longitudinal muscle in human small intestineHead-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonistEffects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxietyIn vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like propertiesRecent advances in the neuropsychopharmacology of serotonergic hallucinogensKynurenine potentiates the DOI head shake in micem-Chlorophenylpiperazine decreases food intake in a test mealAn immunocapture/scintillation proximity analysis of G alpha q/11 activation by native serotonin (5-HT)2A receptors in rat cortex: blockade by clozapine and mirtazapine5-HT2C receptor modulation and the treatment of obesity.Citalopram-induced hypophagia is enhanced by blockade of 5-HT(1A) receptors: role of 5-HT(2C) receptors.The prevalence of female sexual dysfunction among migraine patients.Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area.Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signalingMultiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Multiple serotonin receptors: opportunities for new treatments for obesity?Multiple 5-HT receptors in the guinea-pig superior cervical ganglionEvidence for a role for central 5-HT2B as well as 5-HT2A receptors in cardiovascular regulation in anaesthetized rats.Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the ratBehavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations.Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635.Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release.An investigation of the 5-HT2C receptor gene as a migraine candidate gene.Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers.Effect of Hallucinogens on Unconditioned Behavior.Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist.Effect of combined administration of afobazole and 5-HT2b/2c receptor antagonist SB-200646A on neurochemical profile of brain structures in C57Bl/6 and BALB/c mice.Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior.The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study.The role of 5-HT2C receptors in affective disorders.Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety.In vivo Schild regression analyses using nonselective 5-HT2C receptor antagonists in a rat operant behavioral assay.Effects of ritanserin and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the murine elevated plus-maze test of anxiety: an ethopharmacological study.
P2860
Q24317175-CDD3CC8E-DA38-4F90-879A-F477279C5E19Q24595389-A621680E-2E1B-4004-8D0D-F65E3FAA0B2FQ24672386-EB2072A4-9672-4820-9732-6BC20FCA0133Q24679647-1EB7E7AE-0B1C-4A9C-A9A9-33BC52FC3DC8Q24679694-A4EC5AB0-B326-49C0-A5CF-3B9CD90E8650Q27027381-4A11A9EB-7104-44C2-AD13-B021836B86E0Q28258717-2FC15C2E-037A-416F-931D-990E25AACDD1Q28307494-3D2B0D51-8DA1-4CE3-9577-E9E5909D95B7Q28578911-9F84EDB5-23A8-4569-962B-3BABFEE8F826Q33936081-18B1549D-DC07-41E5-B031-295875CAEDB3Q35027938-747C3C6E-07A0-4ED9-AFB4-9F9D09F36B71Q35399494-DFAF1B94-6148-4AC8-B3CD-7BD64D036773Q35757409-4A5FEE9D-DDD2-472C-9A8E-8B249C55F5D2Q35873019-3EDA959D-0DDD-4F47-B6E5-916545D12F55Q36608907-3F941EBC-6D94-42C5-A2C1-215ABCE9B210Q38101499-B5B9B91E-0BE8-4310-9182-968ABED686A9Q38648544-7921FF9D-2035-4600-9F36-9A2E2A860BCAQ41026153-91D315C0-6B02-4116-BC4D-2E7790B910BDQ41908786-9F6EF9B4-2C08-4FFF-8FBC-4FD03725A5F6Q41985535-0483E1B5-F3C7-4E24-8B1A-C3504F4B7719Q42057930-9CCFD239-A9E7-45AB-A5F2-BDA174E99287Q42220908-970C5A45-9AE4-4CE5-B944-BC902C509F58Q42237452-951735A9-F91D-4C3D-B4E0-D832CF195214Q43061538-8632E478-0E38-4D9B-B1E0-D5754DDF010EQ44295040-1B9C45A6-8255-4639-9BA6-035649967348Q44992845-DE052C59-5533-4E7B-A61E-735AB77AF2B5Q45279141-0AE90C4A-6B72-46B7-9A26-63E847B9C434Q45908028-C10D9961-1CF5-40C5-A24A-6259FF97FEA1Q48313857-DEABE0FA-A808-47AF-83BC-AF2863C37D6DQ48370760-B204F976-1178-4B4D-B224-73A297390E4CQ48604122-E59CC838-793B-4180-B977-CFF754BE1C46Q48826724-85E178F6-BC08-4E8A-B39D-94422A39B285Q51126109-F350BD9B-06C0-4666-ACD1-48258D2BBA90Q51990165-0FE36A29-4DB1-4A5B-ACC8-B2F81CDF39E2Q52870855-D4A19481-CA4A-4E88-BFCD-FEB34FB172BA
P2860
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@ast
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@en
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@nl
type
label
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@ast
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@en
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@nl
prefLabel
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@ast
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@en
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@nl
P2093
P2860
P1476
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
@en
P2093
Blackburn TP
Kennett GA
P2860
P304
P356
10.1111/J.1476-5381.1994.TB14808.X
P407
P577
1994-03-01T00:00:00Z